Swiss National Bank Takes Position in Alumis Inc. $ALMS

Swiss National Bank purchased a new stake in Alumis Inc. (NASDAQ:ALMS) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 127,800 shares of the company’s stock, valued at approximately $2,815,000.

Other large investors have also added to or reduced their stakes in the company. Strs Ohio increased its stake in Alumis by 300.0% during the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after acquiring an additional 1,500 shares during the period. Assetmark Inc. bought a new stake in shares of Alumis during the 1st quarter valued at $92,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Alumis by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after purchasing an additional 979 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Alumis by 320.9% in the third quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after purchasing an additional 4,894 shares during the period. Finally, SG Americas Securities LLC bought a new position in shares of Alumis in the first quarter worth $190,000.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ALMS shares. Citigroup reaffirmed a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. Chardan Capital increased their price objective on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, May 19th. HC Wainwright lowered shares of Alumis from a “buy” rating to a “neutral” rating and set a $25.00 target price on the stock. in a report on Friday, May 15th. Morgan Stanley reaffirmed an “overweight” rating and set a $39.00 price target on shares of Alumis in a report on Friday, May 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Alumis in a research report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $40.30.

Insider Activity at Alumis

In other news, insider Sanam Pangali sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $28.00, for a total value of $140,000.00. Following the sale, the insider directly owned 11,111 shares in the company, valued at approximately $311,108. This trade represents a 31.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 33.70% of the company’s stock.

Alumis Stock Performance

Alumis stock opened at $28.95 on Friday. Alumis Inc. has a 52 week low of $3.76 and a 52 week high of $31.35. The stock has a market capitalization of $3.69 billion, a P/E ratio of -14.62 and a beta of -0.73. The stock has a fifty day moving average of $24.96 and a 200-day moving average of $25.10.

Alumis (NASDAQ:ALMS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The business had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.10 million. On average, research analysts forecast that Alumis Inc. will post -2.87 earnings per share for the current year.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.